<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8362">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077504</url>
  </required_header>
  <id_info>
    <org_study_id>CONDUCTOME</org_study_id>
    <nct_id>NCT02077504</nct_id>
  </id_info>
  <brief_title>Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) &quot;CONDUCTOME&quot;</brief_title>
  <acronym>CONDUCTOME</acronym>
  <official_title>Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the correlation between functional MEG analysis of
      the tumor and its periphery and the tumor stage and treatment response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A better tumor grade definition would provide an optimized surgical care, prognosis and
      therapeutical response evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) data in tumor grade prediction</measure>
    <time_frame>1 week before exeresis</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>anatomopathologic and clinical data in tumor grade prediction</measure>
    <time_frame>1 week after exeresis</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of molecules involved in glial cells neuralisation expression in tumor samples</measure>
    <time_frame>Up to 1 month after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral growth modelisation from patient MEG and MRI data</measure>
    <time_frame>Up to 1 month after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cerebral Primitive Tumor With Chirurgical Indication</condition>
  <arm_group>
    <arm_group_label>CONDUCTOME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEG and MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MEG and MRI</intervention_name>
    <description>CONDUCTOME</description>
    <arm_group_label>CONDUCTOME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more or equal than 18 years old

          -  patient affiliated to social security or similarly regime

          -  informed consent form signed

          -  supra-tentorial primitive cerebral tumor

        Exclusion Criteria:

          -  Pregnant women and lactating mothers

          -  Ward of court or under guardianship

          -  Adult unable to express their consent

          -  Person deprived of freedom by judicial or administrative decision

          -  Person hospitalized without their consent

          -  Person under legal protection

          -  Magnetic Resonance Imaging (MRI) contraindication (implanted material non
             MRI-compatible, ferro-magnetic foreign body, claustrophobia)

          -  Patients needed emergency medical care for other pathology

          -  severely altered general health (Performance Status 3 or 4)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François BERGER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Grenoble Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François BERGER, MD, PhD</last_name>
    <phone>+ 33 4 38 78 15 18</phone>
    <email>francois.berger@cea.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
    <phone>+ 33 4 38 78 28 51</phone>
    <email>csandreballester@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CLINATEC</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERGER, MD, PhD</last_name>
      <email>francois.berger@cea.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François BERGER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre KRAINIK, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie GRAND, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique HOFFMANN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel GAY, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline PASTERIS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PAVILLER, dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
